The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis
Authors:
Open Access
- 13 August 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 8
Abstract
Background and Aims: Activation of the inflammasome NLRP3 (NOD-, LRR- and pyrin domain containing 3) contributes to the development of non-alcoholic fatty liver disease (NAFLD) and progression to non-alcoholic steatohepatitis (NASH). Therefore, this study explored the therapeutic effects of a novel and selective NLRP3 antagonist in a murine dietary model of NASH.Methods: Groups of 12-week-old ApoE-/- mice were fed ad lib for 7 weeks with a methionine/choline deficient (MCD) and western diet (WD). After 3 weeks of diet-induced injury, mice were injected i. p. with the NLRP3 antagonist IFM-514 (100 mg/kg body weight) or vehicle (0.5% carmellose) every day, 5 days/week for a further 4 weeks. Several markers of inflammation, fibrosis and steatosis were evaluated. Whole transcriptome sequencing and panel RNA expression analysis (NanoString) were performed.Results: IFM-514 inhibited IL-1β production in mice challenged with 20 mg/kg lipopolysaccharide, and in mouse and human inflammatory cells in vitro. IFM-514 inhibited hepatic inflammation in the in vivo non-alcoholic steatohepatitis model assessed by H&E staining and in the hepatic gene expression of inflammasome-related proinflammatory cytokines. This effect was associated with significant reduction in caspase-1 activation. Similarly, IFM-514 was efficacious in vivo in MDC-fed ApoE-/- mice, markedly reducing portal pressure, Sirius red staining and 4-hydroxyproline content compared to vehicle-treated mice. Moreover, IFM-514 significantly reduced hepatic steatosis in MCD-fed ApoE-/- mice, as evidenced by NAFLD scores, oil red O staining, hepatic triglycerides and gene expression. In WD treated animals, similar trends in inflammation and fibrosis were observed, although not sufficient IFM-514 levels were reached.Conclusion: Overall, IFM-514 reduced liver inflammation and fibrosis, with mild effects on liver steatosis in experimental murine NASH. Blocking of NLRP3 may be an attractive therapeutic approach for NASH patients.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SFB TRR57 P18)
- European Union's Horizon 2020 research and innovation programme (668031)
- H2020 Health (731875)
- Fundación Cellex
This publication has 39 references indexed in Scilit:
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNature Reviews Drug Discovery, 2012
- Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesityNature, 2012
- Inflammasome is a central player in the induction of obesity and insulin resistanceProceedings of the National Academy of Sciences, 2011
- The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistanceNature Medicine, 2011
- Specific Contribution of Methionine and Choline in Nutritional Nonalcoholic SteatohepatitisJournal of Biological Chemistry, 2010
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsNature, 2010
- The InflammasomesCell, 2010
- Hematopoietic Cell-Specific Deletion of Toll-like Receptor 4 Ameliorates Hepatic and Adipose Tissue Insulin Resistance in High-Fat-Fed MiceCell Metabolism, 2009
- Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE–/– miceJournal of Clinical Investigation, 2008
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005